CMS implements Inflation Reduction Act payment increase for qualifying biosimilars
Effective Oct. 1 for five years, the Centers for Medicare & Medicaid Services will pay Average Sales Price plus 8%, rather than ASP plus 6%, for biosimilars whose average sales price does not exceed the price of the reference biological product. The payment increase was included in the Inflation Reduction Act of 2022. For new biosimilars that qualify, the five-year period will begin on the first day of the calendar quarter for which ASP payment for that biosimilar begins under Medicare Part B.
Related News Articles
Headline
The AHA today urged the Medicare Payment Advisory Commission to take specific actions on physician fee schedule payments following recommendations the…
Chairperson's File
Rural hospitals and health systems face big challenges, but together — with a unified voice — we can work to ensure people living in rural communities get the…
Headline
The Department of Health and Human Services March 27 announced a series of actions as part of a department-wide restructuring. The department said the moves…
Headline
The AHA March 27 made a series of recommendations to the Physician‐Focused Payment Model Technical Advisory Committee to address barriers to participating in…
Headline
The Senate Finance Committee March 14 held a confirmation hearing on Mehmet Oz's nomination for administrator of the Centers for Medicare & Medicaid…
Headline
The Medicare Payment Advisory Commission March 13 released its March report to Congress that includes recommendations for hospital and other Medicare payment…